GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Debt-to-Asset

Samsung BioLogics Co (XKRX:207940) Debt-to-Asset : 0.09 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Debt-to-Asset?

Samsung BioLogics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩465,594 Mil. Samsung BioLogics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩1,020,645 Mil. Samsung BioLogics Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩17,336,296 Mil. Samsung BioLogics Co's debt to asset for the quarter that ended in Dec. 2024 was 0.09.


Samsung BioLogics Co Debt-to-Asset Historical Data

The historical data trend for Samsung BioLogics Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co Debt-to-Asset Chart

Samsung BioLogics Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.16 0.15 0.12 0.09

Samsung BioLogics Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.10 0.10 0.06 0.09

Competitive Comparison of Samsung BioLogics Co's Debt-to-Asset

For the Biotechnology subindustry, Samsung BioLogics Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samsung BioLogics Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's Debt-to-Asset falls into.


;
;

Samsung BioLogics Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Samsung BioLogics Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(465594.047 + 1020645.428) / 17336296.35
=0.09

Samsung BioLogics Co's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(465594.047 + 1020645.428) / 17336296.35
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Samsung BioLogics Co  (XKRX:207940) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Samsung BioLogics Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Samsung BioLogics Co Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines